Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.